Insider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $141,150.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 15,000 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $9.41, for a total transaction of $141,150.00. Following the completion of the sale, the director now owns 791,283 shares of the company’s stock, valued at $7,445,973.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Cyrus Harmon also recently made the following trade(s):

• On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.93, for a total transaction of $54,650.00.
• On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.92, for a total transaction of $54,600.00.
• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total transaction of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total transaction of $219,400.00.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $13.29 on Friday. Olema Pharmaceuticals, Inc. has a 52-week low of $6.01 and a 52-week high of $17.79. The firm has a fifty day moving average of $10.44 and a 200-day moving average of $12.17.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). Sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.37 earnings per share for the current year.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth about $35,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth about $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth about $130,000. Caxton Associates LP bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth about $166,000. Finally, Entropy Technologies LP bought a new stake in shares of Olema Pharmaceuticals in the 1st quarter worth about $161,000. Institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on OLMA. Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Tuesday. Finally, The Goldman Sachs Group started coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $22.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.